A solid dispersion comprising, in essentially non-crystalline form such that no more than about 5% crystallinity is observed by X-ray diffraction analysis, a compound of Formula I where: R 0 is halo; R 1 and R 2 are H or are independently methyl or methoxy; R 3 and R 4 are independently methyl or methoxy if R 1 and R 2 are H, or are H if R 1 and R 2 are independently methyl or methoxy; A 1 and A 2 are each independently CH or N; R 5 is C 1-4 alkyl or haloalkyl, C 1-4 alkylsulfonyl or haloalkylsulfonyl, halo, nitro or cyano; X is -O- or -NH-; Y is -(CH 2) n - where n is 0, 1, 2 or 3; and R 6 is an unsubstituted or substituted 3- to 7-membered carbocyclic or heterocyclic ring, or is NR 7 R 8; wherein, if R 6 is NR 7 R 8, R 7 and R 8 are each independently H or R 9 -(CH 2) m - groups, no more than one of R 7 and R 8 is H, each R 9 is independently a 3- to 7-membered carbocyclic or heterocyclic ring, optionally substituted with no more than two Z 1 groups as defined below, and each m is independently 0 or 1; and wherein, if R 6 is a substituted carbocyclic or heterocyclic ring, substituents thereon are no more than two Z 1 groups and/or no more than one Z 2 group, Z 1 groups being independently selected from the group consisting of (a) C 1-4 alkyl, C 2-4 alkenyl, C 1-4 alkoxy, C 1-4 alkylthio, C 1-4 alkylamino, C 1-4 alkylsulfonyl, C 1-4 alkylsulfonylamino, C 1-4 alkylcarbonyl, C 1-4 alkylcarbonylamino and C 1-4 alkylcarboxy, each optionally substituted with one or more substituents independently selected from the group consisting of halo, hydroxy, C 1-4 alkoxy, amino, C 1-4 alkylamino, di-(C 1-4 alkyl)amino and cyano, (b) halo, (e) hydroxy, (f) amino and (g) oxo groups, and Z 2 being (i) a further 3- to 6-membered carbocyclic or heterocyclic ring, optionally substituted with no more than two Z 1 groups as defined above, or (ii) NR 7 R 8 where R 7 and R 8 are as defined above; or a pharmaceutically acceptable salt thereof; wherein the compound of Formula I or the pharmaceutically acceptable salt thereof is dispersed in a solid matrix that comprises (a) at least one pharmaceutically acceptable water-soluble polymeric carrier and (b) at least one pharmaceutically acceptable surfactant. R 0 is halo; R 1 and R 2 are H or are independently methyl or methoxy; R 3 and R 4 are independently methyl or methoxy if R 1 and R 2 are H, or are H if R 1 and R 2 are independently methyl or methoxy; A 1 and A 2 are each independently CH or N; R 5 is C 1-4 alkyl or haloalkyl, C 1-4 alkylsulfonyl or haloalkylsulfonyl, halo, nitro or cyano; X is -O- or -NH-; Y is -(CH 2) n - where n is 0, 1, 2 or 3; and R 6 is an unsubstituted or substituted 3- to 7-membered carbocyclic or heterocyclic ring, or is NR 7 R 8; wherein, if R 6 is NR 7 R 8, R 7 and R 8 are each independently H or R 9 -(CH 2) m - groups, no more than one of R 7 and R 8 is H, each R 9 is independently a 3- to 7-membered carbocyclic or heterocyclic ring, optionally substituted with no more than two Z 1 groups as defined below, and each m is independently 0 or 1; and wherein, if R 6 is a substituted carbocyclic or heterocyclic ring, substituents thereon are no more than two Z 1 groups and/or no more than one Z 2 group, Z 1 groups being independently selected from the group consisting of (a) C 1-4 alkyl, C 2-4 alkenyl, C 1-4 alkoxy, C 1-4 alkylthio, C 1-4 alkylamino, C 1-4 alkylsulfonyl, C 1-4 alkylsulfonylamino, C 1-4 alkylcarbonyl, C 1-4 alkylcarbonylamino and C 1-4 alkylcarboxy, each optionally substituted with one or more substituents independently selected from the group consisting of halo, hydroxy, C 1-4 alkoxy, amino, C 1-4 alkylamino, di-(C 1-4 alkyl)amino and cyano, (b) halo, (e) hydroxy, (f) amino and (g) oxo groups, and Z 2 being (i) a further 3- to 6-membered carbocyclic or heterocyclic ring, optionally substituted with no more than two Z 1 groups as defined above, or (ii) NR 7 R 8 where R 7 and R 8 are as defined above; or a pharmaceutically acceptable salt thereof; wherein the compound of Formula I or the pharmaceutically acceptable salt thereof is dispersed in a solid matrix that comprises (a) at least one pharmaceutically acceptable water-soluble polymeric carrier and (b) at least one pharmaceutically acceptable surfactant.